Omicron BA.1/BA.2 infections in triple-vaccinated individuals enhance a diverse repertoire of mucosal and blood immune responses
Hornsby, H.; Nicols, A. R.; Longet, S.; Liu, C.; Tomic, A.; Angyal, A.; Kronsteiner, B.; Tyerman, J. K.; Tipton, T.; Zhang, P.; Gallis Ramalho, M.; Supasa, P.; Selvaraj, M.; Abraham, P.; Neale, I.; Ali, M.; Barratt, N. A.; Nell, J. M.; Gustafsson, L.; Strickland, S.; Grouneva, I.; Rostron, T.; Moore, S. C.; Hering, L. M.; Dobson, S. L.; Bibi, S.; Mongkolsapaya, J.; Lambe, T.; Wootton, D.; Hall, V.; Hopkins, S.; Dong, T.; Barnes, E.; Screaton, G.; Richter, A.; Turtle, L.; Rowland-Jones, S. L.; Carroll, M.; Duncan, C. J. A.; Klenerman, P.; Dunachie, S. J.; Payne, R. P.; de Silva, T. I.; The PITC
Show abstract
Pronounced immune escape by the SARS-CoV-2 Omicron variant has resulted in large numbers of individuals with hybrid immunity, generated through a combination of vaccination and infection. Based primarily on circulating neutralizing antibody (NAb) data, concerns have been raised that omicron breakthrough infections in triple-vaccinated individuals result in poor induction of omicron-specific immunity, and that a history of prior SARS-CoV-2 in particular is associated with profound immune dampening. Taking a broader and comprehensive approach, we characterized mucosal and blood immunity to both spike and non-spike antigens following BA.1/BA.2 infections in triple mRNA-vaccinated individuals, with and without a history of previous SARS-CoV-2 infection. We find that the majority of individuals increase BA.1/BA.2/BA.5-specific NAb following infection, but confirm that the magnitude of increase and post-omicron titres are indeed higher in those who were infection-naive. In contrast, significant increases in nasal antibody responses are seen regardless of prior infection history, including neutralizing activity against BA.5 spike. Spike-specific T cells increase only in infection-naive vaccinees; however, post-omicron T cell responses are still significantly higher in previously-infected individuals, who appear to have maximally induced responses with a CD8+ phenotype of high cytotoxic potential after their 3rd mRNA vaccine dose. Antibody and T cell responses to non-spike antigens also increase significantly regardless of prior infection status, with a boost seen in previously-infected individuals to immunity primed by their first infection. These findings suggest that hybrid immunity induced by omicron breakthrough infections is highly dynamic, complex, and compartmentalised, with significant immune enhancement that can help protect against COVID-19 caused by future omicron variants.
Matching journals
The top 8 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Streptococcus pneumoniae colonisation associates with impaired adaptive immune responses against SARS-CoV-2 96%
- Dose-dependent regulation of immune memory responses against HIV by saponin monophosphoryl lipid A nanoparticle adjuvant 96%
- Host immunological responses facilitate development of SARS-CoV-2 mutations in patients receiving monoclonal antibody treatments 96%
Similar papers in this journal
- Anti-SARS-CoV-2 Antibodies Persist for up to 13 Months and Reduce Risk of Reinfection 96%
- The BNT162b2 mRNA SARS-CoV-2 vaccine induces transient afucosylatedIgG1 in naive but not antigen-experienced vaccinees 96%
- Dynamics of humoral and cellular immune responses after homologous and heterologous SARS-CoV-2 vaccination with ChAdOx1 nCoV-19 and BNT162b2 96%
Similar papers in this journal
- Study on the mucosal and serological immune response to the Novel Coronavirus (SARS-CoV-2) vaccines 97%
- Long-term systemic and mucosal SARS-CoV-2 IgA response and its association with persistent smell and taste disorders 96%
- Immune and behavioral correlates of protection against symptomatic post-vaccination SARS-CoV-2 infection 96%
Similar papers in this journal
- Airway antibodies emerge according to COVID-19 severity and wane rapidly but reappear after SARS-CoV-2 vaccination 97%
- Durability of ChAdOx1 nCov-19 (AZD1222) vaccination in people living with HIV - responses to SARS-CoV-2, variants of concern and circulating coronaviruses 97%
- Vaccine Breakthrough Infection with the SARS-CoV-2 Delta or Omicron (BA.1) Variant Leads to Distinct Profiles of Neutralizing Antibody Responses 96%
Similar papers in this journal
- Immune Responses in Fully Vaccinated Individuals Following Breakthrough Infection with the SARS-CoV-2 Delta Variant in Provincetown, Massachusetts 97%
- Loss of recognition of SARS-CoV-2 B.1.351 variant spike epitopes but overall preservation of T cell immunity 97%
- SARS-CoV-2 Omicron neutralization by therapeutic antibodies, convalescent sera, and post-mRNA vaccine booster 96%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.